Evidence map›Paper›PMID 41915196›Full record

ArticleArchives of toxicology2026

The nitrovinyl moiety determines the cyto- and genotoxic profiles of β-nitrostyrene derivatives: evidence from in silico and in vitro evaluation.

Jan Sündermann, Stella Marie Reamon-Buettner, Sabrina Wilde, Annette Bitsch, Christina Ziemann

Abstract read
In one paragraph

Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jan SündermannFraunhofer Institute for Toxicology and Experimental Medicine ITEM, Nikolai-Fuchs-Straße 1, 30625, Hannover, Germany. jan.suendermann@item.fraunhofer.de.ORCID 0000-0002-8288-932X
Stella Marie Reamon-BuettnerFraunhofer Institute for Toxicology and Experimental Medicine ITEM, Nikolai-Fuchs-Straße 1, 30625, Hannover, Germany.ORCID 0000-0001-9872-5613
Sabrina WildeLyomark Pharma GmbH, Keltenring 17, 82041, Oberhaching, Germany.
Annette BitschFraunhofer Institute for Toxicology and Experimental Medicine ITEM, Nikolai-Fuchs-Straße 1, 30625, Hannover, Germany.ORCID 0000-0003-1539-2871
Christina ZiemannFraunhofer Institute for Toxicology and Experimental Medicine ITEM, Nikolai-Fuchs-Straße 1, 30625, Hannover, Germany.ORCID 0000-0002-3238-5385

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-Nitrostyrene, an important intermediate in chemical industry, shows relevant anti-proliferative and pro-apoptotic potential and has thus been suggested for potential use in tumor chemotherapy. If not derivatized, β-nitrostyrene is however, highly reactive and possess (geno)toxic potential. To decipher structural elements relevant for biological activity, crucial for both, chemical risk assessment and potential drug development, a panel of nine structural derivatives of β-nitrostyrene, was put together. It included structures with and without nitrovinyl moiety and was based on fingerprint similarity, QSAR-based mutagenicity alerts, and literature reports. It comprised simple structures like styrene and more complex structures such as 2-methoxy-5-[(E)-2-nitroethenyl]phenol. In vitro experiments in human WS1 and mouse L5178/TK

Indexed as

MutagensStyrenesVinyl CompoundsAnimalsCell Line, TumorComet AssayComputer SimulationDNA DamageHumansMiceMutagenicity TestsQuantitative Structure-Activity Relationshipbeta-nitrostyreneMutagensStyrenesVinyl CompoundsClastogenicityComet assayCytotoxicityGenotoxicitypH3 (S10)QSARStructural similarityβ-nitrostyreneγH2A.X

Identifiers

PMID41915196
PMCPMC13221336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.